Mifamurtide (Mepact®)

Assessment Status Rapid Review Complete
Drug Mifamurtide
Brand Mepact®
Indication For the treatment of osteosarcoma.
Assessment Process
Rapid review commissioned 22/06/2010
Rapid review completed 13/07/2010
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

A formal PEA is required to demonstrate value for money prior to reimbursement.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.